Introducing Entirety Biomedical – A New Era in Surgical Innovation

Magsorbeo is now Entirety Biomedical! With a fresh brand identity and a renewed vision, they are leading the way in next-generation absorbable metal implants. Their innovative Curasorb implants are designed to restore natural physiology, eliminate follow-up surgeries, and prioritize long-term patient wellbeing. This transformation reflects their commitment to advancing surgical solutions for a healthier, metal-free future!

Akadeum Life Sciences Among Top SE MI Startup Deals

Congratulations to Akadeum Life Sciences for being recognized by Crain’s Detroit Business as a Top 8 deal among Southeast Michigan startups in Q2! Their cutting-edge technology eliminates the need for cell separation instruments, dramatically streamlining cell therapy workflows in both time and cost.

The full article is available in Crain’s Detroit Business; subscription required.

MichBio Members Leading Michigan’s Innovation Momentum

Ann Arbor SPARK, University of Michigan, and Michigan State University, all valued MichBio members, were among the inaugural awardees of the Michigan Innovation Fund. This groundbreaking $60 million fund is dedicated to fueling Michigan’s entrepreneurial ecosystem, fostering startup growth and driving innovation across the state.

Congressional Advocates Seek Expedited Disbursement of Critical NIH Funding

U.S. Senator Katie Britt and 13 Senate colleagues are urging the release of NIH funds, emphasizing the risk of delaying critical research and undermining trust. Their advocacy highlights the impact of funding suspensions, which have already led to significant NIH grant terminations affecting billions in research.

Discover the broader implications and the senators’ call for action.

SBIR/STTR Reauthorization Update: Legislative Efforts Intensify as Program Deadline Approaches

With the September 30 deadline fast approaching, lawmakers are working to reauthorize the SBIR/STTR programs, vital lifelines for funding high-tech small businesses. Key proposals focus on strengthening oversight, expanding access for underserved communities, and addressing commercialization challenges. These programs contribute over $4 billion annually to innovation, making their reauthorization crucial.

Stay updated on the latest developments and what they mean for the industry.

Controversial New Patent Fee Model Emerges

A new value-based patent fee model under consideration could reshape innovation incentives by tying costs to a patent’s potential value. While the initiative aims to boost federal revenue, critics warn of risks to startups and small inventors, including higher costs and legal complexities. The potential impact on innovation and entrepreneurial ventures has sparked significant debate.

>> FDA Appoints Biotech Executive as Top Drug Regulator Under RFK Jr.

>> NATO Innovation Fund Invests in First Biotech: What’s to come?

>> Medtronic’s Flagship Insulin Pump Nets European Approvals for Type 2 Diabetes, Pregnancy and Young Children

>> Novartis Drops Up to $1B+ for Drug Discovery Deal with Matchpoint

ARPA-H FRONT Program Tackles Brain Function Restoration

ARPA-H has launched the groundbreaking FRONT program (Functional Repair of Neocortical Tissue), leveraging neurodevelopmental principles and stem cell technology to regenerate brain tissue and restore motor control, vision, speech, and more. This initiative aims to address irreversible damage caused by strokes, injuries, and neurodegenerative diseases. 

• Solution Summary Due: August 18, 2025  
• Full Proposal Due: September 25, 2025  

Learn more and review the solicitation for details and requirements.